LYMPHOID NEOPLASIA A human monoclonal antibody drug and target discovery platform for B-cell chronic lymphocytic leukemia based on allogeneic hematopoietic stem cell transplantation and phage display
نویسندگان
چکیده
Allogeneic hematopoietic stem cell transplantation (alloHSCT) is the only potentially curative treatment available for patients with B-cell chronic lymphocytic leukemia (B-CLL). Here, we show that post-alloHSCT antibody repertoires can be mined for the discovery of fully human monoclonal antibodies to B-CLL cellsurface antigens. Sera collected from B-CLL patients at defined times after alloHSCT showed selective binding to primary B-CLL cells. Pre-alloHSCT sera, donor sera, and control sera were negative. To identify post-alloHSCT serum antibodies and subsequently B-CLL cell-surface antigens they recognize, we generated a human antibody-binding fragment (Fab) library from post-alloHSCT peripheral blood mononuclear cells and selected it on primary B-CLL cells by phage display. A panel of Fab with B-CLL cell-surface reactivity was strongly enriched. Selection was dominated by highly homologous Fab predicted to bind the same antigen. One Fab was converted to immunoglobulin G1 and analyzed for reactivity with peripheral blood mononuclear cells from B-CLL patients and healthy volunteers. Cell-surface antigen expression was restricted to primary B cells and up-regulated in primary B-CLL cells. Mining post-alloHSCT antibody repertoires offers a novel route to discover fully human monoclonal antibodies and identify antigens of potential therapeutic relevance to B-CLL and possibly other cancers. Trials described herein were registered at www. clinicaltrials.gov as nos. NCT00055744 and NCT00003838. (Blood. 2009;114: 4494-4502)
منابع مشابه
A human monoclonal antibody drug and target discovery platform for B-cell chronic lymphocytic leukemia based on allogeneic hematopoietic stem cell transplantation and phage display Category: Transplantation Running head: Mining antibody repertoires after transplantation
*Corresponding author: Dr. Christoph Rader, Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 9000 Rockville Pike, Building 10 CRC, Room 3-3150, Bethesda, MD 20892-1203 Tel: (301) 451-2235; Fax: (301) 480-3431; e-mail: [email protected] Blood First Edition Paper, prepublished online August 10, 2009; DOI 10...
متن کاملA human monoclonal antibody drug and target discovery platform for B-cell chronic lymphocytic leukemia based on allogeneic hematopoietic stem cell transplantation and phage display.
Allogeneic hematopoietic stem cell transplantation (alloHSCT) is the only potentially curative treatment available for patients with B-cell chronic lymphocytic leukemia (B-CLL). Here, we show that post-alloHSCT antibody repertoires can be mined for the discovery of fully human monoclonal antibodies to B-CLL cell-surface antigens. Sera collected from B-CLL patients at defined times after alloHSC...
متن کاملNovel immune-based treatment strategies for chronic lymphocytic leukemia.
Immune-based treatments represent a new group of therapeutic strategies for patients with cancer, including chronic lymphocytic leukemia (CLL), that employ immune effector mechanisms. Among these strategies is passive immunotherapy with monoclonal antibody, alone or in combination with chemotherapy. Active immunotherapy strategies currently under development include vaccines, administration of ...
متن کاملGPI-Anchored Fibromodulin as a Novel Target in Chronic Lymphocytic Leukemia: Diagnostic and Therapeutic Implications
Background: We have previously reported the aberrant expression of Fibromodulin (FMOD) in patients with chronic lymphocytic leukemia (CLL). Although FMOD has been considered as a cytoplasmic or secretory protein, we discovered the cell surface expression of FMOD in leukemic B cells via anchoring with glycosylphosphatidylinositol (GPI). Objective: To evaluate FM...
متن کاملInfectious toxicity using alemtuzumab Alemtuzumab is a humanized monoclonal antibody directed against CD52, a non-modulating glycosylated peptide antigen that is highly expressed on B-cell in chronic lymphocytic leukemia (CLL) and on normal lym-
Alemtuzumab is a humanized monoclonal antibody directed against CD52, a non-modulating glycosylated peptide antigen that is highly expressed on B-cell in chronic lymphocytic leukemia (CLL) and on normal lymphocytes. CD52 is expressed on virtually all lymphocytes at various stages of differentiation, as well as on monocytes, macrophages and eosinophils; it is not expressed on granulocytes (<5%) ...
متن کامل